The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Monocyte Chemotactic Protein-1 Mediates Prostate Cancer–Induced Bone Resorption
Abstract
Prostate cancer preferentially metastasizes to bone, resulting in high mortality. Strategies to inhibit prostate cancer metastasis include targeting both tumor-induced osteoblastic lesions and underlying osteoclastic activities. We and others have previously shown that blocking receptor activator of nuclear factor-κB ligand (RANKL) partially blocks tumor establishment and progression in bone in murine models. However, levels of RANKL in the cell lines used in these studies were very low, suggesting that soluble factors other than RANKL may mediate the cancer-induced osteoclast activity. To identify these factors, a human cytokine antibody array was used to measure cytokine expression in conditioned medium collected from primary prostate epithelial cells (PrEC), prostate cancer LNCaP and its derivative C4-2B, and PC3 cells. All prostate cancer cells produced high amounts of monocyte chemotactic protein-1 (MCP-1) compared with PrEC cells. Furthermore, levels of interleukin (IL)-6, IL-8, GROα, ENA-78, and CXCL-16 were higher in PC3 than LNCaP. These results were confirmed by ELISA. Finally, human bone marrow mononuclear cells (HBMC) were cultured with PC3 conditioned medium. Although both recombinant human MCP-1 and IL-8 directly stimulated HBMC differentiation into osteoclast-like cells, IL-8, but not MCP-1, induced bone resorption on dentin slices with 21 days of culture in the absence of RANKL. However, the conditioned medium–induced bone resorption was inhibited by MCP-1 neutralizing antibody and was further synergistically inhibited with IL-8 antibody, indicating that MCP-1, in addition to IL-8, mediates tumor-induced osteoclastogenesis and bone resorption. MCP-1 may promote preosteoclast cell fusion, forming multinucleated tartrate-resistant acid phosphatase–positive osteoclast-like cells. This study may provide novel therapeutic targets for treatment of prostate cancer skeletal metastasis. [Cancer Res 2007;67(8):3646–53]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J., Dai, J., Qi, Y., Lin, D.-L., Smith, P., Strayhorn, C., Mizokami, A., Fu, Z., Westman, J., & Keller, E. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11685 · Cited by 452
Self-citation
Cited by
Targeting Macrophages in Cancer: From Bench to Bedside
Poh, A. R., & Ernst, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00049 · Cited by 501
Bone metastasis: mechanisms and therapeutic opportunities
Suva, L. J., Washam, C., Nicholas, R. W., & Griffin, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.227 · Cited by 424
Loberg, R. D., Ying, C., Craig, M., Day, L. L., Sargent, E., Neeley, C., Wojno, K., Snyder, L. A., Yan, L., & Pienta, K. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1286 · Cited by 333
Sandhu, S. K., Papadopoulos, K., Fong, P. C., Patnaik, A., Messiou, C., Olmos, D., Wang, G., Tromp, B. J., Puchalski, T. A., Balkwill, F., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2099-8 · Cited by 272
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis
Zhang, J., Patel, L., & Pienta, K. J. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.009 · Cited by 261
Self-citation
Metadata
- Authors
- Lu, Y., Cai, Z., Xiao, G., Keller, E. T., Mizokami, A., Yao, Z., Roodman, G. D., & Zhang, J.
- Venue
- Cancer Research
- Published
- 2007-04-15
- Volume
- 67
- Issue
- 8
- Pages
- 3646-3653
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2124755056
- Cited by
- 162
- References
- 1
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monocyte Chemotactic Protein-1 Mediates Prostate Cancer–Induced Bone Resorption. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-1210
- The paper
- Lu, Y., Cai, Z., Xiao, G., Keller, E. T., Mizokami, A., Yao, Z., Roodman, G. D., & Zhang, J. (2007). Monocyte Chemotactic Protein-1 Mediates Prostate Cancer–Induced Bone Resorption. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-1210
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.